MedTrace Logo

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

NCT01811212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-04-03

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.

Conditions

  • Poorly Differentiated Thyroid Gland Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Stage I Thyroid Gland Follicular Carcinoma
  • Stage I Thyroid Gland Papillary Carcinoma
  • Stage II Thyroid Gland Follicular Carcinoma
  • Stage II Thyroid Gland Papillary Carcinoma
  • Stage III Thyroid Gland Follicular Carcinoma
  • Stage III Thyroid Gland Papillary Carcinoma
  • Stage IVA Thyroid Gland Follicular Carcinoma
  • Stage IVA Thyroid Gland Papillary Carcinoma
  • Stage IVB Thyroid Gland Follicular Carcinoma
  • Stage IVB Thyroid Gland Papillary Carcinoma
  • Stage IVC Thyroid Gland Follicular Carcinoma
  • Stage IVC Thyroid Gland Papillary Carcinoma
  • Tall Cell Variant Thyroid Gland Papillary Carcinoma
  • Thyroid Gland Oncocytic Follicular Carcinoma

Interventions

DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Manisha Shah · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-08
Primary Completion
2015-07-13
Completion
2017-10-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811212 on ClinicalTrials.gov